Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Pharmaceutical
Aclaris Therapeutics stock has taken a battering again, after the Phase IIb ATI-450-RA-202 trial was found to have missed its primary and secondary endpoints. 14 November 2023
Pharmaceutical
UK-based Kelso Pharma today revealed it has taken its first step in its European expansion strategy by agreeing to acquire Italy’s Velit Biopharma which, like Kelso is a specialty pharma company. 13 November 2023
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines and two biosimilars for approval at its November 2023 meeting. 11 November 2023
Biotechnology
Swiss pharma giant Novartis has released positive new data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib. 10 November 2023
Pharmaceutical
Indian biotech firm Biocon says that its subsidiary, Biocon Biologics, has inked a deal with Eris Lifesciences which will see it divest its dermatology and nephrology branded formulations business unit in India that is mostly comprised of its legacy small-molecule brands. 9 November 2023
Pharmaceutical
Spanish drugmaker Almirall left investors less than impressed with its latest financial results. 9 November 2023
Biotechnology
Swiss biotech MoonLake Immunotherapeutics has announced positive top-line results from its global Phase II ARGO trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with active psoriatic arthritis (PsA). 6 November 2023
Biotechnology
San Diego, USA-based biotech AnaptysBio’s ground breaking Phase III trial results for imsidolimab, a novel inhibitor, bring renewed hope to patients battling generalized pustular psoriasis (GPP). 3 November 2023
Biotechnology
Adding to recent regulatory approvals in the USA and European Union, pharma giant Pfizer can now add the UK to the geographies where its alopecia treatment can be marketed. 1 November 2023
Biosimilars
The US Food and Drug Administration (FDA) yesterday announced it has approved US biotech major Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. 1 November 2023
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze